946598-40-9

Usage

Uses

Used in Pharmaceutical Industry:
2-FLUORO-4-MORPHOLINOBENZOIC ACID is used as a potential therapeutic agent for its anti-inflammatory and anti-cancer properties. Its unique structure allows it to interact with biological targets, offering new avenues for the treatment of various diseases.
Used in Medicinal Chemistry Research:
2-FLUORO-4-MORPHOLINOBENZOIC ACID is utilized as a valuable candidate for further research and development. Its distinctive chemical features make it an interesting subject for exploring new drug mechanisms and potential applications in the treatment of a range of conditions.
Used in Biological Assays:
2-FLUORO-4-MORPHOLINOBENZOIC ACID is employed in various biological assays to evaluate its efficacy and safety as a potential pharmaceutical agent. These assays help in understanding its mechanism of action and its impact on different biological systems.

Upstream product

• 1056475-77-4 C₄H₁₀BNO₃ 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 

Relevant academic research and scientific papers

Rational development of 4-aminopyridyl-based inhibitors targeting trypanosoma cruzi CYP51 as anti-chagas agents

A new series of 4-aminopyridyl-based lead inhibitors targeting Trypanosoma cruzi CYP51 (TcCYP51) has been developed using structure-based drug design as well as structure-property relationship (SPR) analyses. The screening hit starting point, LP10 (KD ≤ 42 nM; EC50 = 0.65 μM), has been optimized to give the potential leads 14t, 27i, 27q, 27r, and 27t, which have low-nanomolar binding affinity to TcCYP51 and significant activity against T. cruzi amastigotes cultured in human myoblasts (EC50 = 14-18 nM for 27i and 27r). Many of the optimized compounds have improved microsome stability, and most are selective against human CYPs 1A2, 2D6, and 3A4 (50% inhibition at 1 μM). A rationale for the improvement in microsome stability and selectivity of inhibitors against human metabolic CYP enzymes is presented. In addition, the binding mode of 14t with the Trypanosoma brucei CYP51 (TbCYP51) orthologue has been characterized by X-ray structure analysis.